ABL BIO INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26,000 KRW | -1.52% |
|
+12.80% | +5.69% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2024 | 2025 |
|---|---|---|---|---|
| Capitalization 1 | 1,041,424 | 1,099,129 | 1,245,206 | - |
| Enterprise Value (EV) 1 | 1,041,424 | 1,099,129 | 1,245,206 | 1,245,206 |
| P/E ratio | -23.8 x | - | -57.6 x | -43.1 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | 16.8 x | 35.6 x | 44.5 x |
| EV / Revenue | - | 16.8 x | 35.6 x | 44.5 x |
| EV / EBITDA | - | 454 x | -56.6 x | -41.5 x |
| EV / FCF | - | - | -14 x | -12.8 x |
| FCF Yield | - | - | -7.15% | -7.79% |
| Price to Book | - | - | 21.2 x | 40.4 x |
| Nbr of stocks (in thousands) | 47,123 | 47,788 | 47,893 | - |
| Reference price 2 | 22,100 | 23,000 | 26,400 | 26,400 |
| Announcement Date | 8/12/22 | 3/15/23 | - | - |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2024 | 2025 |
|---|---|---|---|---|
| Net sales 1 | - | 65.33 | 35 | 28 |
| EBITDA 1 | - | 2.42 | -22 | -30 |
| EBIT 1 | - | 0.1186 | -24 | -31 |
| Operating Margin | - | 0.18% | -68.57% | -110.71% |
| Earnings before Tax (EBT) 1 | - | - | -22 | -29 |
| Net income 1 | -43.56 | - | -22 | -29 |
| Net margin | - | - | -62.86% | -103.57% |
| EPS 2 | -927.0 | - | -458.0 | -612.0 |
| Free Cash Flow 3 | - | - | -89,000 | -97,000 |
| FCF margin | - | - | -254,285.71% | -346,428.57% |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 8/12/22 | 3/15/23 | - | - |
1KRW in Billions2KRW3KRW in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2024 | 2025 |
|---|---|---|---|---|
| Net Debt | - | - | - | - |
| Net Cash position | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow 1 | - | - | -89,000 | -97,000 |
| ROE (net income / shareholders' equity) | - | - | -31.2% | -64.3% |
| ROA (Net income/ Total Assets) | - | - | -13.8% | -22.1% |
| Assets 2 | - | - | 159.4 | 131.2 |
| Book Value Per Share 3 | - | - | 1,248 | 654.0 |
| Cash Flow per Share | - | - | - | - |
| Capex 2 | - | - | - | - |
| Capex / Sales | - | - | - | - |
| Announcement Date | 8/12/22 | 3/15/23 | - | - |
1KRW in Million2KRW in Billions3KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +5.69% | 919M | |
| -2.98% | 102B | |
| +1.91% | 96.29B | |
| +2.13% | 22.18B | |
| -15.53% | 21.2B | |
| -9.21% | 18.31B | |
| -39.98% | 17.38B | |
| -15.77% | 16.36B | |
| +5.15% | 13.97B | |
| +32.41% | 12.17B |
- Stock Market
- Equities
- A298380 Stock
- Financials ABL Bio Inc.
